ArticleFrontiers in oncology2024

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Toshio Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.